MCID: BCL006
MIFTS: 65

B-Cell Lymphomas

Categories: Blood diseases, Cancer diseases, Immune diseases, Rare diseases

Aliases & Classifications for B-Cell Lymphomas

MalaCards integrated aliases for B-Cell Lymphomas:

Name: B-Cell Lymphomas 38 76 73
B-Cell Lymphoma 12 53 29 15
Lymphoma, B-Cell 53 44 40
B-Cell Lymphocytic Neoplasm 12
Lymphoma B-Cell 55

Classifications:



External Ids:

Disease Ontology 12 DOID:707
MeSH 44 D016393
NCIt 50 C27907 C3457
SNOMED-CT 68 1929004
UMLS 73 C0079731

Summaries for B-Cell Lymphomas

NIH Rare Diseases : 53 B-cell lymphoma refers to types of non-Hodgkin lymphoma that are characterized by abnormalities of the "B-cells" (a type of white blood cell that makes antibodies to help fight infection). The condition may grow and spread slowly with few symptoms (also known as indolent lymphoma) or may be very aggressive with severe symptoms. When present, signs and symptoms may include swollen lymph nodes in the neck, armpit, or groin; abdominal pain; fatigue; fever; night sweats; and/or weight loss. The underlying cause of B-cell lymphoma is poorly understood. However, the condition can be associated with genetic abnormalities, environmental factors, viruses, immunodeficiency states, and connective-tissue disorders. Treatment is based on many factors, including the severity of the condition and the associated signs and symptoms.

MalaCards based summary : B-Cell Lymphomas, also known as b-cell lymphoma, is related to t-cell/histiocyte rich large b cell lymphoma and marginal zone b-cell lymphoma. An important gene associated with B-Cell Lymphomas is MIR20A (MicroRNA 20a), and among its related pathways/superpathways are Development EGFR signaling pathway and NF-kappaB Signaling. The drugs Adcetris and Bexxar have been mentioned in the context of this disorder. Affiliated tissues include b cells, t cells and bone, and related phenotypes are hematopoietic system and immune system

Disease Ontology : 12 A non-Hodgkin lymphoma that has material basis in B cells.

Wikipedia : 76 Lymphoma is a group of blood cancers that develop from lymphocytes (a type of white blood cell). The... more...

Related Diseases for B-Cell Lymphomas

Diseases in the B-Cell Lymphomas family:

T-Cell Lymphoma 1a

Diseases related to B-Cell Lymphomas via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 626)
# Related Disease Score Top Affiliating Genes
1 t-cell/histiocyte rich large b cell lymphoma 34.6 BCL6 MME
2 marginal zone b-cell lymphoma 34.5 BCL10 BCL6 CCND1 FOXP1 IRF4 MALT1
3 relapsed/refractory diffuse large b-cell lymphoma 34.5 FOXP1 IRF4
4 nodal marginal zone b-cell lymphoma 34.4 BCL6 MALT1
5 primary cutaneous marginal zone b-cell lymphoma 34.4 BCL10 IRF4 MALT1
6 primary mediastinal large b-cell lymphoma 34.4 BCL6 FOXP1 IRF4 MYC
7 diffuse large b-cell lymphoma 34.3 BCL6 FOXP1 HOTAIR IRF4 MALT1 MME
8 intravascular large b-cell lymphoma 34.3 BCL6 MME
9 high grade b-cell lymphoma with myc and/ or bcl2 and/or bcl6 rearrangement 34.0 BCL6 MYC
10 lymphoma, mucosa-associated lymphoid type 34.0 BCL10 BCL6 CCND1 FOXP1 IRF4 MALT1
11 splenic marginal zone lymphoma 33.3 BCL6 MALT1 PAX5
12 follicular lymphoma 33.0 BCL10 BCL6 CCND1 IRF4 MME MYC
13 primary effusion lymphoma 32.8 BCL6 IRF4 MALT1 MYC
14 mature b-cell neoplasm 32.4 BCL6 MME MYC PVT1
15 reticulosarcoma 32.4 BCL6 CCND3 PAX5
16 burkitt lymphoma 32.4 BCL6 CCND3 MME MYC PAX5 PVT1
17 lymphoma 32.2 BCL10 BCL6 CCND1 GAS5 MALT1 MYC
18 lymphoma, hodgkin, classic 31.2 BCL6 MIR20A MME PAX5 PVT1
19 nodular lymphocyte predominant hodgkin lymphoma 31.0 BCL6 PAX5
20 leukemia, chronic lymphocytic 31.0 BCL10 BCL6 CCND1 PAX5
21 composite lymphoma 30.9 BCL6 PAX5
22 lymphocytic leukemia 30.9 HOTAIR MME MYC PAX5
23 plasmacytoma 30.8 IRF4 MYC PVT1
24 central nervous system lymphoma 30.7 BCL6 FOXP1 MALT1
25 cll/sll 30.6 CCND1 MME PAX5
26 follicular lymphoma 1 30.5 BCL10 BCL6
27 bladder lymphoma 30.5 MME PAX5
28 lymphoma, non-hodgkin, familial 30.5 BCL10 BCL6 CCND1 CCND3 CDKN1B IRF4
29 mantle cell lymphoma 30.5 BCL6 CCND1 CCND3 CDKN1B GAS5 MALAT1
30 lung lymphoma 30.1 BCL6 MALT1 PAX5
31 intestinal disease 30.1 BCL6 CCND1 MYC
32 chromosomal triplication 30.1 BCL6 MALT1
33 retinoblastoma 29.7 CCND1 CCND3 HOTAIR MALAT1
34 leukemia, acute myeloid 29.7 HOTAIR MALAT1 MME MYC TUG1
35 cholangiocarcinoma 29.6 CCND1 CDKN1B MALAT1 MME TUG1
36 squamous cell carcinoma 29.4 CCND1 CDKN1B HOTAIR MALAT1 TUG1
37 myeloma, multiple 29.3 CCND1 CCND3 GAS5 HOTAIR IRF4 MALAT1
38 thyroid cancer, nonmedullary, 1 29.3 GAS5 HOTAIR MALAT1 PVT1
39 glioblastoma 29.2 CCND1 CDKN1B GAS5 HOTAIR MALAT1 MYC
40 small cell cancer of the lung 29.2 HOTAIR MALAT1 MYC PAX5 TUG1
41 lung cancer susceptibility 3 29.1 CCND1 GAS5 HOTAIR MALAT1 TUG1
42 renal cell carcinoma, nonpapillary 29.0 GAS5 HOTAIR MALAT1 MME PVT1 TUG1
43 osteogenic sarcoma 28.8 GAS5 HOTAIR MALAT1 PVT1 TUG1
44 hepatocellular carcinoma 28.7 CCND1 GAS5 HOTAIR MALAT1 MIR20A MYC
45 adamantinoma of long bones 28.7 CCND1 GAS5 HOTAIR MALAT1 MYC PVT1
46 bladder cancer 28.7 CCND1 GAS5 HOTAIR MALAT1 MYC PVT1
47 gastric cancer 28.6 CCND1 CDKN1B GAS5 HOTAIR MALAT1 MIR20A
48 pancreatic cancer 28.5 CCND1 GAS5 HOTAIR MALAT1 MIR20A PVT1
49 breast cancer 28.4 CCND1 CCND3 CDKN1B GAS5 HOTAIR MALAT1
50 lung cancer 28.4 CCND1 CDKN1B GAS5 HOTAIR MALAT1 MIR20A

Graphical network of the top 20 diseases related to B-Cell Lymphomas:



Diseases related to B-Cell Lymphomas

Symptoms & Phenotypes for B-Cell Lymphomas

MGI Mouse Phenotypes related to B-Cell Lymphomas:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.85 BCL10 BCL6 CCND1 CCND3 CDKN1B IRF4
2 immune system MP:0005387 9.7 BCL10 BCL6 CCND1 CCND3 CDKN1B IRF4
3 neoplasm MP:0002006 9.1 CCND1 CCND3 CDKN1B IRF4 MYC PAX5

Drugs & Therapeutics for B-Cell Lymphomas

FDA approved drugs:

(show all 9)
# Drug Name Active Ingredient(s) 18 Company Approval Date
1
Adcetris 18 49 BRENTUXIMAB VEDOTIN Seattle Genetics August 2011
2
Bexxar 18 49 TOSITUMOMAB; IODINE I 131 TOSITUMOMAB Corixa June 2003
3
Intron A 18 49 INTERFERON ALFA-2B Schering-Plough December 1997/ December 1995/ March 1997
4
Mozobil 18 49 PLERIXAFOR Genzyme December 2008
5
Revlimid 18 49 LENALIDOMIDE Celgene June 2013
6
Rituxan 18 49 RITUXIMAB Biogen IDEC, Genentech November 1997
7
Treanda 18 49 BENDAMUSTINE HYDROCHLORIDE Cephalon October 2008
8
Zevalin 18 49 IBRITUMOMAB TIUXETAN Biogen IDEC February 2002
9
Zydelig 18 49 IDELALISIB Gilead July 2014

Drugs for B-Cell Lymphomas (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 599)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Prednisolone phosphate Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 302-25-0
2
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 50-24-8 5755
3
Vincristine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 57-22-7, 2068-78-2 5978
4
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 53-03-2 5865
5
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 83-43-2 6741
6
Methylprednisolone hemisuccinate Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 2921-57-5
7
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 6055-19-2, 50-18-0 2907
8
Doxorubicin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 23214-92-8 31703
9
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 50-02-2 5743
10
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 1177-87-3
11
Gemcitabine Approved Phase 4,Phase 2,Phase 3,Phase 1 95058-81-4 60750
12
Cytarabine Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 147-94-4 6253
13
Cisplatin Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 15663-27-1 2767 441203 84093
14
Etoposide Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 33419-42-0 36462
15
Oxaliplatin Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 61825-94-3 43805 6857599 5310940 9887054
16
Epirubicin Approved Phase 4,Phase 3,Phase 2,Not Applicable 56420-45-2 41867
17
Methotrexate Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 59-05-2, 1959-05-2 126941
18
rituximab Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 174722-31-7 10201696
19
Lenograstim Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 135968-09-1
20
Thiotepa Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 52-24-4 5453
21
leucovorin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 58-05-9 6006 143
22
Vindesine Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 59917-39-4, 53643-48-4 40839
23
Ifosfamide Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 3778-73-2 3690
24
Azacitidine Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1 320-67-2 9444
25
Decitabine Approved, Investigational Phase 4,Phase 1,Phase 2,Early Phase 1 2353-33-5 451668
26
Hydrocortisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 50-23-7 5754
27
Hydrocortisone acetate Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 50-03-3
28
Ribavirin Approved Phase 4,Phase 3 36791-04-5 37542
29
Sofosbuvir Approved Phase 4,Phase 2 1190307-88-0 45375808
30
Ledipasvir Approved Phase 4,Phase 2 1256388-51-8 67505836
31
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 59-30-3 6037
32
Prednisolone hemisuccinate Experimental Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 2920-86-7
33
Doxil Approved June 1999 Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 31703
34
Tenofovir Experimental, Investigational Phase 4 147127-20-6 464205
35 Prednisolone acetate Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
36 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
37 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
38 Antineoplastic Agents, Alkylating Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
39 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
40 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
41 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
42 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
43 Immunologic Factors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
44 Topoisomerase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
45 Alkylating Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
46 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
47 Antimitotic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
48 Methylprednisolone acetate Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
49 Antineoplastic Agents, Phytogenic Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
50 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

Interventional clinical trials:

(show top 50) (show all 2023)
# Name Status NCT ID Phase Drugs
1 Treatment of Diffuse Large B Cell Lymphoma Unknown status NCT01949818 Phase 4 Yangzhengxiaoji capsule combined with CHOP regimen;CHOP regimen
2 PEG-rhG-CSF in Patients With Non-Hodgkin Lymphoma Receiving Chemotherapy to Prevent Neutropenia Unknown status NCT02996617 Phase 4 rhG-CSF regimen;Pegylated rhG-CSF regimen
3 To Compare the Efficacy of a Prophylactic Use of Tenofovir by Duration for the Non-Hodgkin's Lymphoma Unknown status NCT02585947 Phase 4 Tenofovir
4 LINFOTARGAM: Treatment With Chemotherapy Plus Rituximab and Highly Active Antiretroviral Therapy in Patients With Diffuse Large B Cell Lymphoma and Infection With the Human Immunodeficiency Virus (HIV) Completed NCT00466258 Phase 4 R-CHOP;Highly active antiretroviral therapy;Central nervous system (CNS) prophylaxis;Prophylaxis of opportunistic infections and support treatment
5 Bone Marrow Transplantation in Treating Patients With Hematologic Cancer Completed NCT00003398 Phase 4 cyclophosphamide;thiotepa
6 Trial for the Treatment of Newly Diagnosed Mature B-Cell Acute Lymphoblastic Leukemia (B-ALL), Burkitt's Non-Hodgkin's Lymphoma (NHL) and Other High-grade Lymphoma in Adults Completed NCT00199082 Phase 4 Adriamycin;Cyclophosphamide;Cytarabine;Dexamethasone/Prednisolone;VP16;Ifosfamide;Methotrexate;G-CSF;Rituximab;Vincristine/Vindesine
7 Treatment of Elderly Patients With Diffuse Large B-cell Lymphoma Recruiting NCT03513601 Phase 4 (R)-CHOP regimen;(R)-CVP regimen
8 A Clinical Trial of Decitabine in Relapse and Refractory Diffuse Large B Cell Lymphoma Recruiting NCT03579082 Phase 4 Decitabine
9 Treatment of Relapsed /Refractory Diffuse Large B Cell Lymphoma Recruiting NCT03376958 Phase 4 Apatinib
10 Reduced Chemotherapy in Low Risk DLBCL Recruiting NCT02752815 Phase 4 Rituximab;Cyclophosphamide;Epirubicin;Vincristine;Prednisone
11 Rituximab (RTX) Therapy in Patients With Active TAO Recruiting NCT02378298 Phase 4 Rituximab;Iv Methylprednisolone;peroral methylprednisolone and Methotrexate
12 A Study of Brentuximab Vedotin in Participants With Relapsed or Refractory Hodgkin Lymphoma Active, not recruiting NCT01990534 Phase 4 Brentuximab vedotin
13 Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib. Enrolling by invitation NCT03229200 Phase 4 Ibrutinib
14 Anti-CD19:TCRζ Chimeric Antigen Receptor-T Cells in the Treatment for CD19+ B Cell Lymphoma Not yet recruiting NCT02992834 Phase 4
15 Oral Hepatitis C Treatment for Indolent Lymphoma (OPTImaL) Study Terminated NCT02717949 Phase 4 sofosbuvir/ledipasvir;sofosbuvir;Ribavirin
16 Biocell Natural Killer Mixture in Diffuse Large B Cell Lymphoma (DLBCL) Patients Unknown status NCT00846157 Phase 3
17 Phase II Randomized Study With R-DHAP +/- Bortezomib as Induction Therapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) Patients Eligible to Transplantation. BR-DHAP Versus R-DHAP. Unknown status NCT01805557 Phase 2, Phase 3 R-DHAP;BR-DHAP
18 Dose Dense Chemotherapy + Rituximab +/-Intensified High Dose Chemoimmunotherapy With Support of Peripheral Autologous Stem Cell in Diffuse Large B-Cell Lymphoma Unknown status NCT00499018 Phase 3 Rituximab;Ciclofosfamide;Doxorubicina;Vincristina;Prednisone;Pegfilgrastim;Mitoxantrone;ARA-C;Lenograstim;BCNU;ARA-C;VP-16;Ciclofosfamide;Doxorubicina;Vincristina
19 A Study Comparing the Efficacy and Safety Between I-CHOP and R-CHOP in Untreated CD20-Positive Diffuse Large B-cell Lymphoma Patients Unknown status NCT02867566 Phase 3 IBI301 plus CHOP;Rituximab plus CHOP
20 MabionCD20® Compared to MabThera® in Lymphoma Patients Unknown status NCT02617485 Phase 3 Rituximab;Doxorubicin;Vincristine;Cyclophosphamide;prednisone
21 30Gy Versus 40Gy Involved-field Radiotherapy for Localized Diffuse Large B Cell Lymphoma Achieving CR After Chemotherapy Unknown status NCT01156259 Phase 3
22 Multiple Fields Radiotherapy Versus Intravenous Rituximab in the Treatment of Indolent Cutaneous Lymphomas B-cell With Multiple or Recurrent Lesions Unknown status NCT02867553 Phase 3 rituximab
23 TREatment of degeNerative and Neoplastic Diseases With Rituximab Unknown status NCT01277172 Phase 2, Phase 3
24 Study Comparing the Zevalin Regimen With no Further Treatment in DLBCL Patients Who Are in Complete Remission After CHOP-R Unknown status NCT00322218 Phase 3 Zevalin Therapeutic Regimen
25 Incidence of Hepatitis B Virus (HBV) Reactivation in HBsAg Negative/HBcAb Positive Lymphoma Patients Treated With RCHOP Unknown status NCT01210287 Phase 2, Phase 3 nucleoside analog reverse transcriptase inhibitor
26 Combination Chemotherapy in Treating Children With Non-Hodgkin's Lymphoma Unknown status NCT00003650 Phase 3 asparaginase;cyclophosphamide;cytarabine;daunorubicin hydrochloride;dexamethasone;etoposide;mercaptopurine;methotrexate;methylprednisolone;mitoxantrone hydrochloride;prednisone;vincristine sulfate
27 Epratuzumab in Treating Patients With Non-Hodgkin's Lymphoma Unknown status NCT00022685 Phase 3
28 Rituximab Maintenance Therapy in Aggressive CD20 (Cluster of Differentiation Antigen 20) Positive Lymphoma and Mantle Cell Lymphoma Unknown status NCT01933711 Phase 3 rituximab
29 Immunotherapy in Peripheral T Cell Lymphoma - the Role of Alemtuzumab in Addition to Dose Dense CHOP Unknown status NCT00725231 Phase 3 chemotherapy
30 Helicobacter – Lymphoma – Radiation Part I: Eradication, Part II: Radiation Unknown status NCT00154440 Phase 3 proton pump inhibitor;clarithromycin;amoxicillin;metronidazole
31 Ketamine Hydrochloride and Best Pain Management in Treating Cancer Patients With Neuropathic Pain Unknown status NCT01316744 Phase 3 ketamine hydrochloride
32 Early Hospital Discharge or Standard Inpatient Care in Cancer Patients Receiving Antibiotics for Febrile Neutropenia Unknown status NCT00445497 Phase 3 amoxicillin-clavulanate potassium;ciprofloxacin
33 Fludarabine and Rituximab With or Without Pixantrone in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin Lymphoma Unknown status NCT00551239 Phase 3 fludarabine phosphate;pixantrone dimaleate
34 Epoetin Alfa or Epoetin Beta With or Without Iron Infusion in Treating Anemia in Patients With Cancer Unknown status NCT00482716 Phase 3
35 Combination Chemotherapy With or Without Interferon Alfa in Treating Patients With Low-Grade Non-Hodgkin's Lymphoma Unknown status NCT00003639 Phase 3 chlorambucil;dexamethasone;idarubicin
36 Interferon Alfa-2b Following Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory Hodgkin's Disease or Non-Hodgkin's Lymphoma Unknown status NCT00003924 Phase 3
37 Levofloxacin Compared With Cefepime in Treating Cancer Patients With Fever and Neutropenia Unknown status NCT00020865 Phase 3 cefepime hydrochloride;levofloxacin
38 Monoclonal Antibodies in Detecting Residual Disease in Patients Who Have Been Treated for Non-Hodgkin's Lymphoma Unknown status NCT00003338 Phase 2, Phase 3
39 Radiolabeled Monoclonal Antibody in the Detection and Staging of Patients With Non-Hodgkin's Lymphoma Unknown status NCT00003337 Phase 3
40 Combination Chemotherapy With or Without Idarubicin and Peripheral Stem Cell Transplantation in Treating Patients With Leukemia or Myelodysplastic Syndrome Unknown status NCT00002989 Phase 3 busulfan;cyclophosphamide;idarubicin;melphalan
41 Combination Chemotherapy With or Without Rituximab in Treating Older Patients With Non-Hodgkin's Lymphoma Unknown status NCT00052936 Phase 3 CHOP regimen;cyclophosphamide;doxorubicin hydrochloride;prednisone;vincristine sulfate
42 LMBA02 Protocol for Patients With a Burkitt Lymphoma Unknown status NCT00180882 Phase 3 rituximab
43 Study of Lenalidomide to Evaluate Safety and Effectiveness in Patients With Diffuse Large B-Cell Lymphoma (DLBCL) Completed NCT01197560 Phase 2, Phase 3 Lenalidomide;Gemcitabine;Oxaliplatin;Rituximab;Etoposide
44 Treatment of Mature B-cell Lymphoma/Leukaemia Completed NCT00162656 Phase 3 half cyclophosphamide;without COPADM3;mini CYVE, without 3 maintenance courses;LMB B;LMB C
45 Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy Completed NCT00790036 Phase 3 Everolimus;Everolimus Placebo
46 A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA) Completed NCT01287741 Phase 3 Rituximab;Obinutuzumab;Cyclophosphamide;Doxorubicin;Vincristine;Prednisone
47 Rituximab+Standard CHOP vs Rituximab+Bi-weekly CHOP for Untreated Stage III/IV Low-grade B-cell Lymphoma (JCOG0203) Completed NCT00147121 Phase 2, Phase 3 Rituximab + Standard CHOP;Rituximab + Bi-weekly CHOP
48 A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1, 2 or 3a Completed NCT01724021 Phase 3 Cyclophosphamide, Hydroxydaunorubicin, Oncovin, Prednisone/Prednisolone (CHOP);Cyclophosphamide, Vincristine, Prednisone/Prednisolone (CVP);Bendamustine;Rituximab;Rituximab;Rituximab;Rituximab
49 A Multicentre, Randomized Phase III Study of Rituximab as Maintenance Treatment Versus Observation in Patients With Aggressive B-cell Lymphoma: NHL-13 Completed NCT00400478 Phase 3 Rituximab
50 A Randomised Evaluation of Molecular Guided Therapy for Diffuse Large B-cell Lymphoma With Bortezomib Completed NCT01324596 Phase 3 Intravenous;Bortezomib

Search NIH Clinical Center for B-Cell Lymphomas

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about B-Cell Lymphomas cell therapies at LifeMap Discovery.

Cochrane evidence based reviews: lymphoma, b-cell

Genetic Tests for B-Cell Lymphomas

Genetic tests related to B-Cell Lymphomas:

# Genetic test Affiliating Genes
1 B-Cell Lymphoma 29

Anatomical Context for B-Cell Lymphomas

MalaCards organs/tissues related to B-Cell Lymphomas:

41
B Cells, T Cells, Bone, Bone Marrow, Breast, Lymph Node, Lung

Publications for B-Cell Lymphomas

Articles related to B-Cell Lymphomas:

(show top 50) (show all 5897)
# Title Authors Year
1
Plasma fibrinogen level as possible prognostic biomarker in diffuse large B-cell lymphoma. ( 30198830 )
2019
2
Efficacy and tolerability of rituximab and reduced-dose cyclophosphamide, doxorubicin, vincristine, and prednisolone therapy for elderly patient with diffuse large B-cell lymphoma. ( 30101679 )
2019
3
Predictive value of interim positron emission tomography in diffuse large B-cell lymphoma: a systematic review and meta-analysis. ( 30141066 )
2019
4
Intravascular large B-cell lymphoma presenting with diffusely increased pulmonary fluorodeoxyglucose uptake without corresponding CT abnormality. ( 30510608 )
2019
5
Cutaneous B-Cell Lymphoma. ( 30497672 )
2019
6
miR‑101 regulates the cell proliferation and apoptosis in diffuse large B‑cell lymphoma by targeting MEK1 via regulation of the ERK/MAPK signaling pathway. ( 30365139 )
2019
7
An Evidence-based Review of Anti-CD20 Antibody-containing Regimens for the Treatment of Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Diffuse Large B-cell Lymphoma, or Follicular Lymphoma. ( 29934061 )
2018
8
Ectopic expression of transcription factor BATF3 induces B-cell lymphomas in a murine B-cell transplantation model. ( 29662618 )
2018
9
A Rare Manifestation of Primary Bone Lymphoma: Solitary Diffuse Large B-Cell Lymphoma of the Little Finger. ( 29398333 )
2018
10
Preclinical efficacy and biological effects of the oral proteasome inhibitor ixazomib in diffuse large B-cell lymphoma. ( 29416618 )
2018
11
Autologous stem cell transplantation for primary mediastinal B-cell lymphoma: long-term outcome and role of post-transplant radiotherapy. A report of the European Society for Blood and Marrow Transplantation. ( 29463854 )
2018
12
T cell/histiocyte-rich large B cell lymphoma: incidence, demographic disparities, and long-term outcomes. ( 29845599 )
2018
13
Extranodal diffuse large B-cell lymphomas: A retrospective case series and review of the literature. ( 29721249 )
2018
14
Ulcerated necrobiosis lipoidica: A cutaneous granulomatous reaction associated with systemic B-cell lymphoma. ( 29770790 )
2018
15
Clinical Response to CHOP vs. R-CHOP in Adult Patients with Diffuse Large B-Cell Lymphomas ( 29801398 )
2018
16
Obesity negatively impacts outcome in elderly female patients with aggressive B-cell lymphomas treated with R-CHOP: results from prospective trials of the German high grade non-Hodgkin's lymphoma trial group. ( 29193018 )
2018
17
Orthodeoxia as a presentation of intravascular large B cell lymphoma. ( 29796279 )
2018
18
Very low-dose versus standard dose radiation therapy for indolent primary cutaneous B-cell lymphomas: A retrospective study. ( 29332711 )
2018
19
Panobinostat in combination with rituximab in heavily pretreated diffuse large B-cell lymphoma: Results of a phase II study. ( 29956350 )
2018
20
Massive splenomegaly due to B-cell lymphoma: A case report. ( 29885916 )
2018
21
Down-regulated miR-148b increases resistance to CHOP in diffuse large B-cell lymphoma cells by rescuing Ezrin. ( 29966970 )
2018
22
Molecular Fingerprinting of Anatomically and Temporally Distinct B-Cell Lymphoma Samples by Next-Generation Sequencing to Establish Clonal Relatedness. ( 29979613 )
2018
23
Pulmonary extranodal marginal zone B-cell lymphoma of mucosa-associated lymph tissue: A case report and literature review. ( 29519992 )
2018
24
Computer-driven quantitative image analysis in the assessment of tumor cell and T cell features in diffuse large B cell lymphomas. ( 29362889 )
2018
25
High frequency and prognostic value of<i>MYD88</i>L265P mutation in diffuse large B-cell lymphoma with R-CHOP treatment. ( 29403563 )
2018
26
Intravascular Large B-Cell Lymphoma Mimicking Temporal Arteritis. ( 29854538 )
2018
27
End-of-treatment and serial PET imaging in primary mediastinal B-cell lymphoma following dose-adjusted-EPOCH-R: A paradigm shift in clinical decision making. ( 29748435 )
2018
28
Metabolic heterogeneity on baseline 18FDG-PET/CT scan is a predictor of outcome in primary mediastinal B-cell lymphoma. ( 29720487 )
2018
29
Serial chest CT findings of intravascular large B-cell lymphoma of the lungs. ( 29707378 )
2018
30
Vitamin D deficiency and supplementation in patients with aggressive B-cell lymphomas treated with immunochemotherapy. ( 29271084 )
2018
31
Sequential loss of tumor surface antigens following chimeric antigen receptor T-cell therapies in diffuse large B-cell lymphoma. ( 29419431 )
2018
32
Molecular Mechanisms of Disease Progression in Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type during Ibrutinib Therapy. ( 29899297 )
2018
33
CAR T cell therapy for B-cell lymphomas. ( 29909914 )
2018
34
Composite cutaneous lymphoma of diffuse large B-cell lymphoma-leg type and subcutaneous panniculitis-like T-cell lymphoma. ( 29851123 )
2018
35
Primary Liver Diffuse Large B-Cell Lymphoma following Complete Response for Hepatitis C Infection after Direct Antiviral Therapy. ( 29393087 )
2018
36
The Diving Bell and the Butterfly Revisited: A Fatal Case of Locked-in Syndrome in a Man With Epstein-Barr Virus-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified. ( 29623003 )
2018
37
Spontaneous Regression of Primary Cutaneous Diffuse Large B-cell Lymphoma, Leg Type. ( 29508000 )
2018
38
Differential prognostic impact of GELTAMO-IPI in cell of origin subtypes of Diffuse Large B Cell Lymphoma as defined by the Hans algorithm. ( 29978453 )
2018
39
Human herpesvirus-encoded kinase induces B cell lymphomas in vivo. ( 29733294 )
2018
40
Small Cell Variant of Intravascular Large B-Cell Lymphoma: Highlighting a Potentially Fatal and Easily Missed Diagnosis. ( 29850589 )
2018
41
Epstein-Barr Virus-Induced Metabolic Rearrangements in Human B-Cell Lymphomas. ( 29937761 )
2018
42
Meningeal marginal zone B-cell lymphoma: The meningioma trap. ( 29331570 )
2018
43
What is the standard of care for primary mediastinal B cell lymphoma; R-CHOP or DA-EPOCH-R? - Response to Melani etA al. ( 29528099 )
2018
44
Concurrent mucosa-associated lymphoid tissue lymphoma with diffuse large B-cell lymphoma transformation and Hodgkin lymphoma of the neck. ( 29427189 )
2018
45
Role of Radiation Therapy in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Guidelines from the International Lymphoma Radiation Oncology Group. ( 29413279 )
2018
46
Bone Marrow Involvement of Epstein-Barr Virus-Positive Large B-Cell Lymphoma in a Patient with Angioimmunoblastic T-Cell Lymphoma. ( 29214764 )
2018
47
EBV-positive B-cell lymphoma manifestation of the liver in an infant with RAG1 severe combined immunodeficiency disease. ( 29856523 )
2018
48
Isolated superior oblique muscle extranodal marginal zone B cell lymphoma: case report. ( 29755275 )
2018
49
De Novo CD5-Positive Primary Gastric Diffuse Large B-Cell Lymphoma Coexpressing MYC and BCL6: Towards a Proper Subset of Double-Hit, Triple-Hit and, Maybe, Quadruple-Hit B-Cell Lymphomas? ( 29399573 )
2018
50
Primary cutaneous B-cell lymphomas- clinical and histopathologic features, differential diagnosis, and treatment. ( 29719020 )
2018

Variations for B-Cell Lymphomas

Cosmic variations for B-Cell Lymphomas:

9 (show top 50) (show all 82)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM44623 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.487T>A p.Y163N 17:7675125-7675125 4
2 COSM44571 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.581T>G p.L194R 17:7674950-7674950 4
3 COSM10894 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.670G>A p.E224K 17:7674861-7674861 4
4 COSM35908 TNFAIP3 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.2251G>A p.E751K 6:137881197-137881197 4
5 COSM35907 TNFAIP3 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.2209C>A p.Q737K 6:137881155-137881155 4
6 COSM35911 TNFAIP3 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.1354G>T p.E452* 6:137878799-137878799 4
7 COSM35970 TNFAIP3 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.1421C>A p.T474N 6:137878866-137878866 4
8 COSM35913 TNFAIP3 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.905T>C p.L302P 6:137877175-137877175 4
9 COSM35969 TNFAIP3 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.503G>A p.W168* 6:137875704-137875704 4
10 COSM35909 TNFAIP3 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.254G>A p.W85* 6:137871481-137871481 4
11 COSM6987354 STAG2 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.3688A>G p.M1230V 23:124100589-124100589 4
12 COSM6945907 PIM1 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.94G>A p.E32K 6:37170784-37170784 4
13 COSM6975552 PAX5 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.559A>T p.I187F 9:37002693-37002693 4
14 COSM581 NRAS haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.181C>G p.Q61E 1:114713909-114713909 4
15 COSM586 NRAS haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.183A>C p.Q61H 1:114713907-114713907 4
16 COSM562 NRAS haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.34G>T p.G12C 1:114716127-114716127 4
17 COSM564 NRAS haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.35G>A p.G12D 1:114716126-114716126 4
18 COSM574 NRAS haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.38G>T p.G13V 1:114716123-114716123 4
19 COSM566 NRAS haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.35G>T p.G12V 1:114716126-114716126 4
20 COSM5416033 NFKBIE haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.782+5G>A p.? 6:44264977-44264977 4
21 COSM499 HRAS haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.182A>G p.Q61R 11:533874-533874 4
22 COSM6987350 ARID5B haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.793T>G p.F265V 10:62050947-62050947 4
23 COSM307270 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.208T>A p.Y70N 17:7675125-7675125 4
24 COSM307267 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.487T>A p.Y163N 17:7675125-7675125 4
25 COSM307268 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.487T>A p.Y163N 17:7675125-7675125 4
26 COSM3717662 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.487T>A p.Y163N 17:7675125-7675125 4
27 COSM6987351 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.64T>G p.F22V 10:62050947-62050947 4
28 COSM6987353 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.3799A>G p.M1267V 23:124100589-124100589 4
29 COSM307269 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.91T>A p.Y31N 17:7675125-7675125 4
30 COSM3077774 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.295T>C p.C99R 6:394899-394899 4
31 COSM3717661 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.487T>A p.Y163N 17:7675125-7675125 4
32 COSM6986772 TRAF2 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,B cell lymphoma unspecified c.152A>G p.H51R 9:136898892-136898892 2
33 COSM10648 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,B cell lymphoma unspecified c.524G>A p.R175H 17:7675088-7675088 2
34 COSM44910 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,B cell lymphoma unspecified c.403T>A p.C135S 17:7675209-7675209 2
35 COSM10995 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,B cell lymphoma unspecified c.580C>T p.L194F 17:7674951-7674951 2
36 COSM4721653 RICTOR haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,B cell lymphoma unspecified c.3712C>T p.R1238* 5:38950136-38950136 2
37 COSM190567 RHOA haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,B cell lymphoma unspecified c.206T>C p.L69P 3:49368499-49368499 2
38 COSM5274 PTEN haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,B cell lymphoma unspecified c.484G>C p.D162H 10:87933243-87933243 2
39 COSM6987562 PTEN haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,B cell lymphoma unspecified c.331T>G p.W111G 10:87933090-87933090 2
40 COSM5036 PTEN haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,B cell lymphoma unspecified c.202T>C p.Y68H 10:87925550-87925550 2
41 COSM30627 PIK3CA haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,B cell lymphoma unspecified c.3109G>A p.E1037K 3:179234266-179234266 2
42 COSM85940 MYD88 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,B cell lymphoma unspecified c.794T>C p.L265P 3:38141150-38141150 2
43 COSM6987557 MSH6 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,B cell lymphoma unspecified c.493T>C p.F165L 2:47795929-47795929 2
44 COSM2006760 KMT2D haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,B cell lymphoma unspecified c.12952C>T p.Q4318* 12:49030678-49030678 2
45 COSM6987497 KDM6A haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,B cell lymphoma unspecified c.3406A>G p.M1136V 23:45083581-45083581 2
46 COSM6949886 HGF haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,B cell lymphoma unspecified c.986G>T p.W329L 7:81729659-81729659 2
47 COSM6948355 GRIN2A haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,B cell lymphoma unspecified c.2453C>T p.A818V 16:9768993-9768993 2
48 COSM37031 EZH2 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,B cell lymphoma unspecified c.1936T>A p.Y646N 7:148811636-148811636 2
49 COSM37029 EZH2 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,B cell lymphoma unspecified c.1937A>C p.Y646S 7:148811635-148811635 2
50 COSM52944 DNMT3A haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,B cell lymphoma unspecified c.2645G>A p.R882H 2:25234373-25234373 2

Expression for B-Cell Lymphomas

Search GEO for disease gene expression data for B-Cell Lymphomas.

Pathways for B-Cell Lymphomas

Pathways related to B-Cell Lymphomas according to GeneCards Suite gene sharing:

(show all 30)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.43 CCND1 CDKN1B MYC REL
2 12.4 BCL10 BCL6 IRF4 MALT1 PAX5 REL
3
Show member pathways
12.33 BCL10 IRF4 MALT1 REL
4 12.32 CCND1 CDKN1B FOXP1 MIR17 MIR20A MYC
5 12.28 CCND1 CCND3 CDKN1B MYC
6
Show member pathways
12.28 CCND1 CCND3 CDKN1B MYC REL
7 12.2 CCND1 CCND3 CDKN1B MYC
8 12.19 CCND1 CCND3 CDKN1B REL
9
Show member pathways
12.11 CCND1 CCND3 CDKN1B MYC
10
Show member pathways
12.1 CCND1 CCND3 CDKN1B MYC
11 12.1 BCL6 CDKN1B MYC PAX5 REL
12 11.9 CCND1 CDKN1B MYC
13 11.87 BCL6 CCND1 IRF4 MYC
14 11.86 CCND1 CDKN1B MYC
15
Show member pathways
11.81 BCL10 BCL6 IRF4 MALT1 MYC REL
16 11.78 CCND1 CDKN1B MYC
17 11.72 CCND1 CCND3 CDKN1B MYC
18 11.65 CCND3 CDKN1B MYC
19 11.65 CCND1 CDKN1B MYC PAX5
20 11.61 CCND3 CDKN1B MYC
21 11.61 BCL6 CCND1 CCND3 CDKN1B MYC
22 11.59 CCND1 CDKN1B MYC
23 11.54 CCND1 CDKN1B MYC
24
Show member pathways
11.52 CCND1 CDKN1B MYC REL
25 11.47 BCL6 MME PAX5
26
Show member pathways
11.47 CCND1 CCND3 CDKN1B MIR17 MIR20A MYC
27
Show member pathways
11.39 CCND1 CDKN1B MYC
28 11.32 CCND1 CCND3 CDKN1B MYC
29 11.26 CCND1 CCND3 MYC
30 11.2 CCND1 CCND3 MYC REL

GO Terms for B-Cell Lymphomas

Cellular components related to B-Cell Lymphomas according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 CBM complex GO:0032449 8.62 BCL10 MALT1

Biological processes related to B-Cell Lymphomas according to GeneCards Suite gene sharing:

(show all 16)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of transcription by RNA polymerase II GO:0000122 9.93 BCL6 CCND1 CCND3 MYC PAX5 REL
2 cytokine-mediated signaling pathway GO:0019221 9.84 BCL6 CCND1 IRF4 MYC
3 negative regulation of gene expression GO:0010629 9.81 MIR17 MIR20A MYC REL
4 response to estradiol GO:0032355 9.72 CCND1 CDKN1B MYC
5 G1/S transition of mitotic cell cycle GO:0000082 9.7 CCND1 CDKN1B MYC
6 negative regulation of toll-like receptor signaling pathway GO:0034122 9.56 IRF4 MIR17
7 response to molecule of bacterial origin GO:0002237 9.49 BCL10 MALT1
8 positive regulation of cardiac muscle hypertrophy in response to stress GO:1903244 9.48 MIR17 MIR20A
9 negative regulation of B cell apoptotic process GO:0002903 9.43 BCL6 FOXP1
10 regulation of cyclin-dependent protein serine/threonine kinase activity GO:0000079 9.43 CCND1 CCND3 CDKN1B
11 response to fungus GO:0009620 9.4 BCL10 MALT1
12 re-entry into mitotic cell cycle GO:0000320 9.37 CCND1 MYC
13 regulation of T cell receptor signaling pathway GO:0050856 9.32 BCL10 MALT1
14 positive regulation of pulmonary blood vessel remodeling GO:1905111 9.16 MIR17 MIR20A
15 positive regulation of cyclin-dependent protein serine/threonine kinase activity GO:0045737 9.13 CCND1 CCND3 CDKN1B
16 positive regulation of cell cycle GO:0045787 8.92 CCND1 CCND3 CDKN1B MYC

Molecular functions related to B-Cell Lymphomas according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 DNA-binding transcription factor activity GO:0003700 9.73 BCL6 FOXP1 IRF4 MYC PAX5 REL
2 kinase activator activity GO:0019209 9.16 BCL10 MALT1
3 protein self-association GO:0043621 9.13 BCL10 FOXP1 MALT1
4 cyclin-dependent protein serine/threonine kinase activity GO:0004693 8.8 CCND1 CCND3 CDKN1B

Sources for B-Cell Lymphomas

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....